{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:12:38Z","timestamp":1792894358741,"version":"4.5.0"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[1998,1,1]],"date-time":"1998-01-01T00:00:00Z","timestamp":883612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1998,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            A randomized, prospective, double-blind, double-dummy, multicenter study investigated the efficacy and safety of 10 days of oral therapy with grepafloxacin at 400 mg once daily, grepafloxacin at 600 mg once daily, or ciprofloxacin at 500 mg twice daily in 624 patients with acute bacterial exacerbations of chronic bronchitis. At the end of treatment, clinical success (cure or improvement) was achieved for 93% (140 of 151), 88% (137 of 156), and 91% (145 of 160) of patients in the groups receiving grepafloxacin at 400 mg, grepafloxacin at 600 mg, and ciprofloxacin, respectively (clinically evaluable population). At follow-up (14 to 28 days posttreatment), the clinical success rates were 87% (124 of 143), 81% (122 of 151), and 80% (123 of 154) in the groups receiving grepafloxacin at 400 mg and 600 mg and ciprofloxacin, respectively. A total of 379 pathogens were isolated from 290 patients, with the most common isolates being\n            <jats:italic>Moraxella catarrhalis<\/jats:italic>\n            (21%),\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            (20%),\n            <jats:italic>Haemophilus influenzae<\/jats:italic>\n            (18%), and\n            <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n            (7%). For the evaluable population, successful bacteriologic response was obtained at the end of treatment for 96% (92 of 96), 98% (87 of 89), and 92% (82 of 90) of patients receiving grepafloxacin at 400 mg, grepafloxacin at 600 mg, and ciprofloxacin, respectively, and was maintained in 86% (82 of 95), 88% (78 of 89), and 82% (69 of 84) of patients, respectively, at follow-up. All pretreatment\n            <jats:italic>S. pneumoniae<\/jats:italic>\n            isolates were susceptible to grepafloxacin, but two strains were resistant to ciprofloxacin. All treatments were well tolerated, with the most frequently reported drug-related adverse events being nausea, taste perversion, and headache. All drug-related adverse events in the grepafloxacin groups were mild or moderate in severity. This study demonstrates that 10-day courses of grepafloxacin given at 400 or 600 mg once daily were as effective, clinically and bacteriologically, as ciprofloxacin given at 500 mg twice daily for the treatment of acute bacterial exacerbations of chronic bronchitis.\n          <\/jats:p>","DOI":"10.1128\/aac.42.1.114","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:30:08Z","timestamp":1539045008000},"page":"114-120","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":42,"title":["Efficacy and Safety of a 10-Day Course of 400 or 600 Milligrams of Grepafloxacin Once Daily for Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis: Comparison with a 10-Day Course of 500 Milligrams of Ciprofloxacin Twice Daily"],"prefix":"10.1128","volume":"42","author":[{"given":"S.","family":"Chodosh","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Veterans Affairs Outpatient Clinic 111C, Boston, Massachusetts 021141;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lakshminarayan","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Veterans Affairs Hospital 111B, Seattle, Washington 981082;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Swarz","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->International Pharmaceutical Consultants, Inc., Scarsdale, New York 105833; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Breisch","sequence":"additional","affiliation":[{"name":"<!--label omitted: 4-->Otsuka Pharmaceuticals, Inc., Rockville, Maryland 208504"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/15.1.77"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","unstructured":"Ball P. 1995. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 108 (Suppl.) : 43\u201352.","DOI":"10.1378\/chest.108.2_Supplement.43S"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","unstructured":"Baquero F. and E. Loza. 1994. Antibiotic resistance of microorganisms involved in ear nose and throat infections. Pediatr. Infect. Dis. J. 13 (Suppl. 1) : 9\u201314.","DOI":"10.1097\/00006454-199401001-00003"},{"key":"e_1_3_2_5_2","unstructured":"Barry\nA. L.\nIn vitro activities of OPC-17116 and five other fluoroquinolones abstr. 779\nProgram and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy.\n1992\n240\nAmerican Society for Microbiology\nWashington D.C"},{"key":"e_1_3_2_6_2","unstructured":"Bartlett\nJ. G.\nRyan\nK. J.\nSmith\nT. F.\nWilson\nW. R.\nCumitech 7A Laboratory diagnosis of lower respiratory tract infections. Coordinating ed. J. A. Washington II.\n1987\nAmerican Society for Microbiology\nWashington D.C"},{"key":"e_1_3_2_7_2","first-page":"23","article-title":"Drug-resistant Streptococcus pneumoniae\u2014Kentucky and Tennessee","volume":"43","author":"Block S.","year":"1993","unstructured":"Block S. Hendrick J. Wright P. Finger R. Leggiadro R. Appleton M. Drug-resistant Streptococcus pneumoniae\u2014Kentucky and Tennessee. Morbid. Mortal. Weekly Rep. 43 1993 23 25","journal-title":"Morbid. Mortal. Weekly Rep."},{"key":"e_1_3_2_8_2","unstructured":"Chodosh S. 1987. Acute bacterial exacerbations in bronchitis and asthma. Am. J. Med. 82 (Suppl. 4A) : 154\u2013163."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Chodosh S. 1991. Use of quinolones for the treatment of acute exacerbations of chronic bronchitis. Am. J. Med. 91 (Suppl. 6A) : 93S\u2013100S.","DOI":"10.1016\/0002-9343(91)90318-R"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","unstructured":"Chodosh S. J. Tuck K. D. Stottmeier and D. Pizzuto. 1989. Comparison of ciprofloxacin with ampicillin in acute infectious exacerbations of chronic bronchitis. Am. J. Med. 87 (Suppl. 5A) : 107S\u2013112S.","DOI":"10.1016\/0002-9343(89)90035-1"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/0924-8579(93)90031-Y","article-title":"Evaluating the clinical outcomes of respiratory infection","volume":"3","author":"Cole P.","year":"1993","unstructured":"Cole P. Evaluating the clinical outcomes of respiratory infection. Int. J. Antimicrob. Agents 3 1993 S15 S19","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/jac\/35.2.317","article-title":"Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments","volume":"35","author":"Cook P. J.","year":"1995","unstructured":"Cook P. J. Andrews J. M. Wise R. Honeybourne D. Moudgil H. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J. Antimicrob. Chemother. 35 1995 317 326","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/BF02013995","article-title":"Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis","volume":"5","author":"Davies B. I.","year":"1986","unstructured":"Davies B. I. Maesen F. P. V. Baur C. Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. Eur. J. Clin. Microbiol. 5 1986 226 231","journal-title":"Eur. J. Clin. Microbiol."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.5.1208"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","unstructured":"Efthymiopoulos C. S. L. Bramer and A. Maroli. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males. Clin. Pharm. 33 (Suppl. 1) : 1\u20138.","DOI":"10.2165\/00003088-199700331-00003"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1001\/archinte.1990.00390200073014","article-title":"The effect of prescribed daily dose frequency on patient medication compliance","volume":"150","author":"Eisen S. A.","year":"1990","unstructured":"Eisen S. A. Miller D. K. Woodward R. S. The effect of prescribed daily dose frequency on patient medication compliance. Arch. Intern. Med. 150 1990 1881 1884","journal-title":"Arch. Intern. Med."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0732-8893(96)00161-7","article-title":"Tentative interpretive criteria for testing the susceptibility of Streptococcus pneumoniae to eight fluoroquinolones","volume":"26","author":"Fuchs P. C.","year":"1996","unstructured":"Fuchs P. C. Barry A. L. Brown A. D. Tentative interpretive criteria for testing the susceptibility of Streptococcus pneumoniae to eight fluoroquinolones. Diagn. Microbiol. Infect. Dis. 26 1996 23 27","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.11.2528"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.3.573"},{"key":"e_1_3_2_20_2","first-page":"157","article-title":"Pathogenesis of bacterial infections of the respiratory tract","volume":"52","author":"Johnson J. A.","year":"1995","unstructured":"Johnson J. A. Pathogenesis of bacterial infections of the respiratory tract. Br. J. Biomed. Sci. 52 1995 157 161","journal-title":"Br. J. Biomed. Sci."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.8.1726"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/jac\/33.3.647","article-title":"In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study","volume":"33","author":"Marco F.","year":"1994","unstructured":"Marco F. Jones R. N. Hoban D. J. Pignatari A. C. Yamane N. Frei R. In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study. J. Antimicrob. Chemother. 33 1994 647 654","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_23_2","unstructured":"National Committee for Clinical Laboratory Standards\nPerformance standards for antimicrobial susceptibility testing 5th informational supplement document M100-S5.\n1994\nNational Committee for Clinical Laboratory Standards\nVillanova Pa"},{"key":"e_1_3_2_24_2","unstructured":"National Committee for Clinical Laboratory Standards\nPerformance standards for antimicrobial susceptibility testing 6th informational supplement document M100-S6.\n1995\nNational Committee for Clinical Laboratory Standards\nVillanova Pa"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.6.1310"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0011-393X(05)80693-9","article-title":"Comparative safety and efficacy of clarithromycin and three oral cephalosporins in the treatment of outpatients with bacterial bronchitis","volume":"54","author":"Notario G.","year":"1993","unstructured":"Notario G. Siepman N. Devcich K. Guay D. R. P. Comparative safety and efficacy of clarithromycin and three oral cephalosporins in the treatment of outpatients with bacterial bronchitis. Curr. Ther. Res. 54 1993 628 640","journal-title":"Curr. Ther. Res."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/jac\/35.1.230","article-title":"Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci","volume":"35","author":"Pankuch G. A.","year":"1995","unstructured":"Pankuch G. A. Jacobs M. R. Appelbaum P. C. Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J. Antimicrob. Chemother. 35 1995 230 232","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/00012995-199204000-00001","article-title":"Adverse reactions to the fluoroquinolones","volume":"153","author":"Paton J. H.","year":"1992","unstructured":"Paton J. H. Reeves D. S. Adverse reactions to the fluoroquinolones. Adv. Drug React. Bull. 153 1992 575 578","journal-title":"Adv. Drug React. Bull."},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/BF01962081","article-title":"In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones","volume":"11","author":"Sader H. S.","year":"1992","unstructured":"Sader H. S. Erwin M. E. Jones R. N. In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones. Eur. J. Clin. Microbiol. Infect. Dis. 11 1992 372 381","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0732-8893(95)00021-2","article-title":"Tentative criteria for determining the in vitro susceptibilities of Haemophilus influenzae, including quality control parameters to two fluoroquinolones (grepafloxacin and PD 131628)","volume":"21","author":"Sewell D. L.","year":"1995","unstructured":"Sewell D. L. Barry A. L. Tentative criteria for determining the in vitro susceptibilities of Haemophilus influenzae, including quality control parameters to two fluoroquinolones (grepafloxacin and PD 131628). Diagn. Microbiol. Infect. Dis. 21 1995 175 179","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_31_2","first-page":"289","article-title":"The role of antibiotics in the management of acute exacerbations of chronic bronchitis (answers to some commonly asked questions)","volume":"89","author":"Skudlarska B. A.","year":"1992","unstructured":"Skudlarska B. A. Scott G. C. The role of antibiotics in the management of acute exacerbations of chronic bronchitis (answers to some commonly asked questions). Mol. Med. 89 1992 289 293","journal-title":"Mol. Med."},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jac\/31.2.273","article-title":"Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9429 and RP 67829","volume":"31","author":"Spangler S. K.","year":"1993","unstructured":"Spangler S. K. Jacobs M. R. Pankuch G. A. Appelbaum P. C. Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9429 and RP 67829. J. Antimicrob. Chemother. 31 1993 273 280","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jac\/31.4.497","article-title":"The in vitro activities of OPC-17116, a new 5-methyl substituted quinolone","volume":"31","author":"Wise R.","year":"1993","unstructured":"Wise R. Andrews J. M. Brenwald N. The in vitro activities of OPC-17116, a new 5-methyl substituted quinolone. J. Antimicrob. Chemother. 31 1993 487 504","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.42.1.114","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.42.1.114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:41:20Z","timestamp":1645458080000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.42.1.114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1998,1]]}},"alternative-id":["10.1128\/AAC.42.1.114"],"URL":"https:\/\/doi.org\/10.1128\/aac.42.1.114","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,1]]},"assertion":[{"value":"1997-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1997-10-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}